IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IMUNON (Nasdaq: IMNN) reported a third-quarter net loss available to common shareholders of $3.813 million while advancing its ovarian cancer program. The loss compared with $3.429 million a year earlier; loss per share narrowed to $0.64 from $1.16. Nine-month operating cash use was unchanged at $10.2 million. September 30 cash and equivalents totaled $4.039 million, alongside $5.039 million in restricted cash.
The company expects Phase 3 OVATION 3 enrollment to finish by the first quarter of 2029. It entered a development agreement with the National Cancer Institute and exchanged $1.2 million of debt plus accrued interest for non-convertible preferred stock. A proposed ThermoDox rights sale offers milestone payments of up to $16.5 million, subject to development milestones; closing depends on VoxelDox raising $2.5 million. A proposed securities offering remains pending.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointDebt exchange retired $1.2 million plus accrued interest, reducing the A-1 Note balance approximately 43%. 30% of market cap
- Major point. Forward-looking: it has not happened yet and may not happen.ThermoDox sale agreement provides an equity stake in VoxelDox, contingent milestones up to $16.5 million and royalties after commercial approval. 4.1× market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.National Cancer Institute agreement supports clinical and non-clinical development; its Cancer Therapy Evaluation Program will assume regulatory sponsorship.
- Moderate point. Forward-looking: it has not happened yet and may not happen.OVATION 3 enrollment is expected to finish by the first quarter of 2029.
- Minor pointIMNN-001 Phase 2 results showed no cytokine release syndrome or higher immune-related event incidence versus control.
4 minor points
- Minor pointPhase 2 analyses showed local IL-12 delivery, anti-tumor immune responses and improved tumor immune-cell ratios.
- Minor pointPhase 2 residual-disease study review found no new safety signals and recommended continuation without modification.
- Minor pointThird-quarter research and development expenses fell to $1.793 million from $1.899 million a year earlier.
- Minor pointNine-month general and administrative expenses fell to $4.951 million from $5.098 million a year earlier.
Negative
- Major pointDebt exchange issued non-convertible Series B Preferred Stock, without issuing common stock or warrants.
- Moderate pointThird-quarter common-shareholder loss widened to $3.813 million from $3.429 million; per-share loss narrowed to $0.64 from $1.16.
- Moderate point. Forward-looking: it has not happened yet and may not happen.ThermoDox sale closing depends on VoxelDox raising $2.5 million. 62% of market cap
- Moderate pointProposed securities offering remains pending, with its registration statement not yet effective.
- Moderate pointTotal liabilities increased to $9.386 million at September 30, 2026, from $5.226 million at December 31, 2025.
- Moderate pointStockholders’ equity declined to $2.622 million at September 30, 2026, from $7.062 million at December 31, 2025.
3 minor points
- Minor pointNine-month common-shareholder loss widened to $10.895 million from $10.272 million; per-share loss narrowed to $2.01 from $5.53.
- Minor pointThird-quarter general and administrative expenses rose to $1.655 million from $1.577 million, primarily reflecting higher professional fees.
- Minor pointNine-month research and development expenses rose to $5.595 million from $5.291 million a year earlier.
News Explained
The
Key Figures
- Net loss available to common shareholders
- $3.8 million
- Q3 2026; compared with $3.4 million in Q3 2025
- Net loss per share
- $0.64 per share
- Q3 2026; compared with $1.16 per share in Q3 2025
- Operating expenses
- $3.4 million
- Q3 2026; compared with $3.5 million in Q3 2025
- Net loss available to common shareholders
- $10.9 million
- Nine months ended September 30, 2026; compared with $10.3 million in 2025
- Net cash used in operating activities
- $10.2 million
- Nine months ended September 30, 2026; unchanged from the same period in 2025
- Cash and cash equivalents
- $4.0 million
- As of September 30, 2026
- Restricted cash
- $5.0 million
- As of September 30, 2026; additional to cash and cash equivalents
Previous Earnings Reports
-
Reported lower net loss and operating expenses year over year.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
crada regulatory
cytokine release syndrome medical
minimal residual disease medical
interleukin-12 medical
non-convertible financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer
Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by the first quarter of 2029, supported by strong Phase 2 clinical data showing significant overall survival benefit
Conference call to be held today at 11:00 a.m. EST
LAWRENCEVILLE, N.J., Nov. 12, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the three months and nine months ended September 30, 2026, and highlighted recent business updates including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer.
“IMUNON continues to make significant progress in the clinical development of IMNN-001 for advanced ovarian cancer,” said Stacy R. Lindborg, Ph.D., President and Chief Executive Officer of IMUNON. “The data generated to date, our collaboration with the National Cancer Institute, and the favorable safety profile observed across studies support the ongoing advancement of the program and its potential to provide a transformative treatment for women with this difficult disease. We believe the OVATION 3 study is well positioned, with a broad patient population, two planned interim analyses, and a development strategy designed to support efficient execution and evaluation of the treatment’s potential benefit.”
“We have also taken steps to continue to sharpen our strategic focus and strengthen IMUNON’s financial position. Through our agreement to transition ThermoDox® to a dedicated development partner and our recent debt-for-equity exchange, we are demonstrating the disciplined approach to capital allocation that we believe is essential to advancing our most significant clinical opportunity while preserving opportunities for future value creation. As we look ahead, our priorities remain clear: execute OVATION 3, build on the growing body of evidence supporting IMNN-001 and advance a potentially transformative new treatment option for women who urgently need better outcomes.”
RECENT DEVELOPMENTS
IMNN-001:
On July 23, 2026, the Company announced that translational and clinical data on IMNN-001 were presented at the inaugural AACR Conference on Drug Discovery and Development (AACR D3), held July 21–24, 2026, in Boston. The presentation included findings from the randomized Phase 2 OVATION 2 study demonstrating that IMNN-001 was safe and well-tolerated, achieved local delivery of IL-12, and induced anti-tumoral immune responses, with no cytokine release syndrome or higher incidence of immune-related events observed in the experimental arm compared with control. Translational analyses indicated that IMNN-001 enhanced favorable ratios of CD8+ T cells to regulatory T cells and CD8+ to CD4+ cells in tumors and the tumor microenvironment, consistent with previously reported associations with improved outcomes. These findings support the ongoing pivotal Phase 3 OVATION 3 trial, which is designed to confirm the safety and survival benefit of IMNN-001 in frontline advanced ovarian cancer.
On September 10, 2026, the Company announced it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health. Under the CRADA, the NCI’s Cancer Therapy Evaluation Program (CTEP), which will assume regulatory sponsorship, will support further clinical and non-clinical development of IMNN-001 under the NCI Experimental Therapeutics (NExT) Program. IMNN-001 is the first gene-based immunotherapy selected by NCI/CTEP for partnered clinical development under a CRADA.
On September 22, 2026, the Company announced that the Independent Data Monitoring Committee (IDMC) overseeing its ongoing Phase 2 minimal residual disease (MRD) translational study of IMNN-001 recommended that the study continue without modification, identifying no new safety signals and confirming comparable safety across both treatment arms.
On September 23, 2026, the Company hosted its 2026 R&D Day in New York, featuring presentations from the lead clinical investigators on the completed Phase 2 OVATION 2 study, the pivotal Phase 3 OVATION 3 study and the Phase 2 MRD study, together with translational data on how IMNN-001 remodels the tumor immune microenvironment. A replay is available on the Scientific Presentations page of the Company’s website, accessible through this webcast link.
On November 6, 2026, the Company announced new translational data from its randomized Phase 2 OVATION 2 study of IMNN-001 in newly diagnosed advanced ovarian cancer. The data are being presented in a poster at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting (SITC 2026), being held November 4–8, 2026, at the Phoenix Convention Center in Phoenix, Arizona.
Corporate Development:
On September 29, 2026, the Company entered into an Exchange Agreement, under which
On October 21, 2026, the Company announced that it had entered into an agreement to sell its rights to ThermoDox®, a heat-activated liposomal formulation of doxorubicin, to VoxelDox Therapeutics, Inc. (“VoxelDox”). Under the agreement, closing of which is contingent on VoxelDox raising
On October 27, 2026, the Company filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed offering of its securities. The registration statement has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
FINANCIAL RESULTS FOR THE THIRD QUARTER 2026
Net loss available to common shareholders for the third quarter of 2026 was
Research and development expenses were
General and administrative expenses increased to
FINANCIAL RESULTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026
Net loss available to common shareholders for the nine months ended September 30, 2026 was
Research and development expenses increased to
General and administrative expenses were
Net cash used in operating activities was
Conference Call and Webcast
The Company will host a conference call to review third quarter 2026 financial results and provide a business update today, November 12, 2026, at 11:00 a.m. EST. To participate in the call, please dial (800) 715-9871 (U.S. and Canada/Toll Free) or (646) 307-1963 (U.S./Toll) and ask for the IMUNON Third Quarter 2026 Financial Results Call (Conference ID 4174261). A live webcast of the call will also be available here.
An audio replay of the call will be available for 90 days and can be accessed at (800) 770-2030 (U.S. and Canada/Toll Free) or (609) 800-9909 (U.S./Toll) using replay access code 4174261#.
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The lead modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials, including one Phase 2 clinical trial (OVATION 2), and is currently being studied in a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. The Company will continue to leverage its modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding expectations regarding the timing and enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Investor Contact:
Valter Pinto
KCSA Strategic Communications
212-896-1254
imunon@kcsa.com
(Tables to Follow)
IMUNON, Inc.
Condensed Consolidated Statements of Operations
(in thousands except per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Operating expenses: Research and development | $ | 1,793 | $ | 1,899 | $ | 5,595 | $ | 5,291 | ||||||||
| General and administrative | 1,655 | 1,577 | 4,951 | 5,098 | ||||||||||||
| Total operating expenses | 3,448 | 3,476 | 10,546 | 10,389 | ||||||||||||
| Loss from operations | (3,448 | ) | (3,476 | ) | (10,546 | ) | (10,389 | ) | ||||||||
| Other (expense) income | (302 | ) | 47 | (267 | ) | 117 | ||||||||||
| Net loss | $ | (3,750 | ) | $ | (3,429 | ) | $ | (10,813 | ) | $ | (10,272 | ) | ||||
| Deemed dividend – preferred stock | (63 | ) | - | (82 | ) | - | ||||||||||
| Net loss available to common shareholders | $ | (3,813 | ) | $ | (3,429 | ) | $ | (10,895 | ) | $ | (10,272 | ) | ||||
| Net loss per common share | ||||||||||||||||
| Basic and diluted | $ | (0.64 | ) | $ | (1.16 | ) | $ | (2.01 | ) | $ | (5.53 | ) | ||||
| Weighted average shares outstanding | ||||||||||||||||
| Basic and diluted | 5,947 | 2,944 | 5,408 | 1,856 | ||||||||||||
IMUNON, Inc.
Selected Balance Sheet Information
(in thousands)
| September 30, 2026 | December 31, 2025 | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 4,039 | $ | 8,781 | ||||
| Advances, deposits on clinical programs and other current assets | 1,799 | 1,943 | ||||||
| Total current assets | 5,838 | 10,724 | ||||||
| Property and equipment | 394 | 530 | ||||||
| Other assets | ||||||||
| Restricted cash | 5,039 | - | ||||||
| Operating lease right-of-use assets | 687 | 984 | ||||||
| Deposits and other assets | 51 | 50 | ||||||
| Total other assets | 5,777 | 1,034 | ||||||
| Total assets | $ | 12,009 | $ | 12,288 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued liabilities | $ | 2,414 | $ | 4,217 | ||||
| Note payable – current portion Note A | 1,380 | - | ||||||
| Operating lease liability – current portion | 445 | 407 | ||||||
| Total current liabilities | 4,239 | 4,624 | ||||||
| Note Payable – Note B | 4,884 | - | ||||||
| Operating lease liability – noncurrent portion | 263 | 602 | ||||||
| Total liabilities | 9,386 | 5,226 | ||||||
| Stockholders' equity | ||||||||
| Preferred stock, including additional paid-in capital | 3,384 | - | ||||||
| Common stock | 62 | 34 | ||||||
| Additional paid-in capital | 431,373 | 428,411 | ||||||
| Accumulated deficit | (432,111 | ) | (421,298 | ) | ||||
| 2,708 | 7,147 | |||||||
| Less: Treasury stock | (86 | ) | (85 | ) | ||||
| Total stockholders' equity | 2,622 | 7,062 | ||||||
| Total liabilities and stockholders' equity | $ | 12,009 | $ | 12,288 | ||||
# # #
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were IMUNON's third-quarter 2026 earnings results?
IMUNON reported a $3.813 million net loss available to common shareholders, or $0.64 per share, compared with $3.429 million, or $1.16 per share, in the third quarter of 2025. Total operating expenses were $3.448 million versus $3.476 million a year earlier.
When does IMUNON expect to complete OVATION 3 enrollment?
IMUNON expects enrollment in the Phase 3 OVATION 3 study to be completed by the first quarter of 2029. The study evaluates IMNN-001 in newly diagnosed advanced ovarian cancer.
How is IMUNON's OVATION 3 trial designed?
OVATION 3 is designed to confirm the safety and survival benefit of IMNN-001 in frontline advanced ovarian cancer. Its design includes a broad patient population and two planned interim analyses, which evaluate study data before the trial concludes.